false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Best of IGCS 2022 Annual Global Meeting
Changing Paradigms in Endometrial Cancer Treatment ...
Changing Paradigms in Endometrial Cancer Treatment - Industry Symposium by Eisai Inc.
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video is a recording of a symposium sponsored by ESAI, where the changing paradigms in endometrial cancer are discussed. The panelists, including Wendell Nauman, Keta Larusso, Jonathan Latiman, and Vicky Mockery, discuss the future of endometrial cancer treatment. They talk about the use of immunotherapy, specifically the combination of lenvatinib and pembrolizumab, and its efficacy in different subtypes of endometrial cancer, such as MMR-deficient and MMR-proficient tumors. The panelists also discuss the management of common side effects of the treatment, including hypertension, diarrhea, and hypothyroidism. The video ends with a discussion on future directions, including ongoing clinical trials and the potential for predictive factors beyond MMR status. Overall, the video provides insights into the current and future treatment landscape of endometrial cancer.
Keywords
endometrial cancer
changing paradigms
immunotherapy
lenvatinib
pembrolizumab
MMR-deficient tumors
MMR-proficient tumors
side effects
hypertension
clinical trials
Contact
education@igcs.org
for assistance.
×